Search

Your search keyword '"Amin Al Olama A"' showing total 6 results
Start Over Author "Amin Al Olama A" Publisher springer science and business media llc
6 results on '"Amin Al Olama A"'

1. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Author

Brian D. Carter, Gert De Meerleer, Michael B. Cook, Paul A. Townsend, Kim De Ruyck, Edward J. Saunders, Christopher A. Haiman, Atushi Takahashi, Sonja I. Berndt, Florence Menegaux, Cezary Cybulski, Barbara Nemesure, Loic Le Marchand, Sune F. Nielsen, Demetrius Albanes, Robert J. Hamilton, Ninghan Feng, Stella Koutros, Stephen J. Chanock, Wei Zheng, Thomas A. Sellers, Rick A. Kittles, Craig C. Teerlink, Stephen N. Thibodeau, Marija Gamulin, Artitaya Lophatananon, Niclas Håkansson, Fredrik Wiklund, Roberta McKean-Cowdin, Yuan Chun Ding, Nora Pashayan, Timothy J. Key, Børge G. Nordestgaard, Shannon K. McDonnell, Jong Y. Park, Laura Fachal, Martin Andreas Røder, Johanna Schleutker, Edward Giovannucci, Anssi Auvinen, Hardev Pandha, Maria Elena Martinez, Mitchell J. Machiela, Gill Barnett, Melissa C. Southey, Graham G. Giles, Barry S. Rosenstein, Stephen Watya, Bernd Holleczek, Pascal Blanchet, Agnieszka Michael, William J. Blot, James L. Mohler, Jack A. Taylor, Sarah L. Kerns, Adam S. Kibel, Piet Ost, Ana Vega, Richard M. Martin, Jennifer J. Hu, Nicholas Mancuso, Yukihide Momozawa, Robert J. MacInnis, Sue A. Ingles, Maureen Sanderson, Kai Uwe Saum, Markus Aly, Robert Szulkin, Davor Lessel, Hermann Brenner, Yves Akoli Koudou, Jan Lubinski, Mina Torres, Anselm Hennis, Eli Marie Grindedal, Csilla Sipeky, Susan L. Neuhausen, Alison M. Dunning, Alicja Wolk, Adam B. Murphy, Brandi Weaver, Mariana C. Stern, Paula Paulo, Stephanie J. Weinstein, Xueying Mao, Tobias Nordström, Neil Fleshner, Tokhir Dadaev, Teuvo L.J. Tammela, Jay H. Fowke, Tomislav Kuliš, Steven Joniau, Yudong Wu, Rosalind A. Eeles, Shan Chao Zhao, Kenneth Muir, Mark N. Brook, Hidewaki Nakagawa, Freddie C. Hamdy, Karina Dalsgaard Sørensen, Linda Steele, Alisha Chou, Dominika Wokołorczyk, Peggy Wan, Martin Eklund, Laurent Brureau, Lisa A. Cannon-Albright, Lilit C. Moss, Daniel J. Schaid, Luc Multigner, Benjamin A. Rybicki, Xin Sheng, Constance Turman, Ron H.N. van Schaik, Radka Kaneva, Zsofia Kote-Jarai, Frank Claessens, Katarina Cuk, Kay-Tee Khaw, Chad D. Huff, Henrik Grönberg, Kathryn L. Penney, Geraldine Cancel-Tassin, Eric A. Klein, Masashi Fujita, Jennifer Cullen, Michael Borre, Jenny L Donovan, Dana C. Crawford, Antonio Gómez-Caamaño, David V. Conti, Manuel Luedeke, Maya Ghoussaini, Janet L. Stanford, Peter Kraft, Ian M. Thompson, Koichi Matsuda, Soo-Hwang Teo, Christopher J. Logothetis, Robin J. Leach, Monique J. Roobol, Manuel R. Teixeira, Jose Esteban Castelao, Sara S. Strom, Vanio Mitev, Stig E. Bojesen, David J. Hunter, Wayne D. Tilley, Jyotsna Batra, Gerald L. Andriole, Christine Neslund-Dudas, Sara Lindström, Guido Jenster, Catherine M. Tangen, William S. Bush, Maren Weischer, Chavdar Slavov, Thomas J. Schnoeller, Javier Llorca, Claire Aukim-Hastie, Nawaid Usmani, Lisa G. Horvath, Daniel W. Lin, Esther M. John, Burcu F. Darst, Milan S. Geybels, Phyllis J. Goodman, Lynne R. Wilkens, Ali Amin Al Olama, Lorelei A. Mucci, Peter Iversen, Christiane Maier, Victoria L. Stevens, Andreia Brandão, Graham Casey, Neil G. Burnet, Ann W. Hsing, Hongwei Zhang, Laura E. Beane Freeman, Susan M. Gapstur, Sara Benlloch, James E. Mensah, Marie-Élise Parent, Jianfeng Xu, Bettina F. Drake, Jeannette T. Bensen, Azad Hassan Abdul Razack, Edward D. Yeboah, David E. Neal, John D. Carpten, Ruth C. Travis, Thomas J. Hoffmann, Thomas Van den Broeck, Jeri Kim, Ali Sahimi, Gemma Castaño-Vinyals, Alexander Lubwama, Leire Moya, Elio Riboli, Douglas F. Easton, Suzanne K. Chambers, Yong-Jie Lu, Melinda C. Aldrich, Manuela Gago-Dominguez, John S. Witte, Matthew Parliament, Gail P. Risbridger, Samantha E.T. Larkin, Lisa F. Newcomb, Fredrick R. Schumacher, Shiv Srivastava, Jasmine Lim, Meir J. Stampfer, Harry Ostrer, Judith A. Clements, Thérèse Truong, Catharine M L West, Zan Sun, Olivier Cussenot, Gyorgy Petrovics, Lovise Maehle, Elizabeth T. H. Fontham, William B. Isaacs, Hui Yi Lin, Rohit Varma, Elaine A. Ostrander, Manolis Kogevinas, Robert N. Hoover, Sandeep Singhal, Antonio Finelli, and Stephen K. Van Den Eeden

Subjects
0303 health sciences, business.industry, Published Erratum, MEDLINE, Genome-wide association study, Computational biology, Biology, medicine.disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Meta-analysis, Genetics, medicine, Susceptibility locus, 06 Biological Sciences, 11 Medical and Health Sciences, Personalized medicine, Genetic risk, business, 030217 neurology & neurosurgery, 030304 developmental biology, Developmental Biology
Abstract

In the version of this article originally published, the names of the equally contributing authors and jointly supervising authors were switched. The correct affiliations are: “These authors contributed equally: David V. Conti, Burcu F. Darst. These authors jointly supervised this work: David V. Conti, Rosalind A. Eeles, Zsofia Kote-Jarai, Christopher A. Haiman.” The error has been corrected in the HTML and PDF versions of the article.

Published
2021

3. Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium

Author

Cezary Cybulski, Børge G. Nordestgaard, Graham G. Giles, Christopher A. Haiman, Nikhil K. Khankari, William J. Blot, Stephen N. Thibodeau, Fredrik Wiklund, Nora Pashayan, Kenneth Muir, Hermann Brenner, Douglas F. Easton, Wei Zheng, Lisa A. Cannon-Albright, Janet L. Stanford, Hardev Pandha, Jyotsna Batra, Manuel R. Teixeira, Harvey J. Murff, Kay-Tee Khaw, Chenjie Zeng, Zsofia Kote-Jarai, Ali Amin Al Olama, Jong Hyuk Park, Ruth C. Travis, Rosalind A. Eeles, Sara Benlloch, Christiane Maier, Johanna Schleutker, Radka Kaneva, Wanqing Wen, Jenny L Donovan, Adam S. Kibel, and Henrik Grönberg

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Epidemiology, Genome-wide association study, Disease, Logistic regression, 03 medical and health sciences, symbols.namesake, Prostate cancer, 0302 clinical medicine, Risk Factors, Internal medicine, Journal Article, medicine, Humans, Mendelian randomisation, chemistry.chemical_classification, omega-3 fatty acids, business.industry, Prostatic Neoplasms, Cancer, ta3121, prostate cancer, ta3122, medicine.disease, omega-6 fatty acids, 3. Good health, Biotechnology, 030104 developmental biology, chemistry, Centre for Surgical Research, 030220 oncology & carcinogenesis, polygenic risk score, Fatty Acids, Unsaturated, Mendelian inheritance, symbols, Etiology, business, Genome-Wide Association Study, polyunsaturated fatty acids, Polyunsaturated fatty acid
Abstract

Background: Prostate cancer is a common cancer worldwide with no established modifiable lifestyle factors to guide prevention. The associations between polyunsaturated fatty acids (PUFAs) and prostate cancer risk have been inconsistent. Using Mendelian randomisation, we evaluated associations between PUFAs and prostate cancer risk.Methods: We used individual-level data from a consortium of 22 721 cases and 23 034 controls of European ancestry. Externally-weighted PUFA-specific polygenic risk scores (wPRSs), with explanatory variation ranging from 0.65 to 33.07%, were constructed and used to evaluate associations with prostate cancer risk per one standard deviation (s.d.) increase in genetically-predicted plasma PUFA levels using multivariable-adjusted unconditional logistic regression.Results: No overall association was observed between the genetically-predicted PUFAs evaluated in this study and prostate cancer risk. However, risk reductions were observed for short-chain PUFAs, linoleic (ORLA=0.95, 95%CI=0.92, 0.98) and α-linolenic acids (ORALA=0.96, 95%CI=0.93, 0.98), among men LA=1.04, 95%CI=1.01, 1.07). For long-chain PUFAs (i.e., arachidonic, eicosapentaenoic, and docosapentaenoic acids), increased risks were observed among men AA=1.05, 95%CI=1.02, 1.08; OREPA=1.04, 95%CI=1.01, 1.06; ORDPA=1.05, 95%CI=1.02, 1.08).Conclusion: Results from this study suggest that circulating ω-3 and ω-6 PUFAs may have a different role in the aetiology of early- and late-onset prostate cancer.

Published
2016

4. Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort

Author

William J. Blot, Jyotsna Batra, Jong Hyuk Park, Cezary Cybulski, Ruth C. Travis, Nora Pashayan, Richard M. Martin, George Davey Smith, Hardev Pandha, Carolina Bonilla, Stephen N. Thibodeau, Fredrik Wiklund, Henrik Grönberg, Zsofia Kote-Jarai, Kenneth Muir, Adam S. Kibel, Sarah J Lewis, Rosalind A. Eeles, Lisa A. Cannon-Albright, Hermann Brenner, Kay-Tee Khaw, Johanna Schleutker, Jenny L Donovan, Graham G. Giles, Manuel R. Teixeira, Freddie C. Hamdy, Janet L. Stanford, Doug Easton, Børge G. Nordestgaard, Ali Amin Al Olama, Sara Benlloch, David E. Neal, Radka Kaneva, Christopher A. Haiman, Mark Lathrop, Christiane Maier, Easton, Douglas [0000-0003-2444-3247], Khaw, Kay-Tee [0000-0002-8802-2903], and Apollo - University of Cambridge Repository

Subjects
Oncology, Gerontology, Male, Prostate cancer, Random Allocation, 0302 clinical medicine, Risk Factors, Odds Ratio, 030212 general & internal medicine, Sexual Maturation, Age of Onset, Medicine(all), Boys, Hazard ratio, General Medicine, Middle Aged, 3. Good health, Centre for Surgical Research, 030220 oncology & carcinogenesis, Menarche, Regression Analysis, ICEP, Research Article, medicine.medical_specialty, Adolescent, Polymorphism, Single Nucleotide, 03 medical and health sciences, Internal medicine, Mendelian randomization, medicine, Humans, Tanner scale, Aged, Neoplasm Staging, business.industry, Puberty, Case-control study, Cancer, Prostatic Neoplasms, Odds ratio, Mendelian Randomization Analysis, medicine.disease, Survival Analysis, United Kingdom, Case-Control Studies, business, Genome-Wide Association Study
Abstract

Background Epidemiological studies have observed a positive association between an earlier age at sexual development and prostate cancer, but markers of sexual maturation in boys are imprecise and observational estimates are likely to suffer from a degree of uncontrolled confounding. To obtain causal estimates, we examined the role of pubertal development in prostate cancer using genetic polymorphisms associated with Tanner stage in adolescent boys in a Mendelian randomization (MR) approach. Methods We derived a weighted genetic risk score for pubertal development, combining 13 SNPs associated with male Tanner stage. A higher score indicated a later puberty onset. We examined the association of this score with prostate cancer risk, stage and grade in the UK-based ProtecT case-control study (n = 2,927), and used the PRACTICAL consortium (n = 43,737) as a replication sample. Results In ProtecT, the puberty genetic score was inversely associated with prostate cancer grade (odds ratio (OR) of high- vs. low-grade cancer, per tertile of the score: 0.76; 95 % CI, 0.64–0.89). In an instrumental variable estimation of the causal OR, later physical development in adolescence (equivalent to a difference of one Tanner stage between pubertal boys of the same age) was associated with a 77 % (95 % CI, 43–91 %) reduced odds of high Gleason prostate cancer. In PRACTICAL, the puberty genetic score was associated with prostate cancer stage (OR of advanced vs. localized cancer, per tertile: 0.95; 95 % CI, 0.91–1.00) and prostate cancer-specific mortality (hazard ratio amongst cases, per tertile: 0.94; 95 % CI, 0.90–0.98), but not with disease grade. Conclusions Older age at sexual maturation is causally linked to a reduced risk of later prostate cancer, especially aggressive disease. Electronic supplementary material The online version of this article (doi:10.1186/s12916-016-0602-x) contains supplementary material, which is available to authorized users.

Published
2016

5. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript

Author

Kote-Jarai, Z., primary, Amin Al Olama, A., additional, Leongamornlert, D., additional, Tymrakiewicz, M., additional, Saunders, E., additional, Guy, M., additional, Giles, G. G., additional, Severi, G., additional, Southey, M., additional, Hopper, J. L., additional, Sit, K. C., additional, Harris, J. M., additional, Batra, J., additional, Spurdle, A. B., additional, Clements, J. A., additional, Hamdy, F., additional, Neal, D., additional, Donovan, J., additional, Muir, K., additional, Pharoah, P. D. P., additional, Chanock, S. J., additional, Brown, N., additional, Benlloch, S., additional, Castro, E., additional, Mahmud, N., additional, O’Brien, L., additional, Hall, A., additional, Sawyer, E., additional, Wilkinson, R., additional, Easton, D. F., additional, and Eeles, R. A., additional

Published
2011
Full Text
View/download PDF

6. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium

Author

Lophatananon, Artitaya, Stewart-Brown, Sarah, Kote-Jarai, Zsofia, Olama, Ali Amin Al, Garcia, Sara Benlloch, Neal, David E, Hamdy, Freddie C, Donovan, Jenny L, Giles, Graham G, Fitzgerald, Liesel M, Southey, Melissa C, Pharoah, Paul, Pashayan, Nora, Gronberg, Henrik, Wiklund, Fredrik, Aly, Markus, Stanford, Janet L, Brenner, Hermann, Dieffenbach, Aida K, Arndt, Volker, Park, Jong Y, Lin, Hui-Yi, Sellers, Thomas, Slavov, Chavdar, Kaneva, Radka, Mitev, Vanio, Batra, Jyotsna, Spurdle, Amanda, Clements, Judith A, APCB BioResource, PRACTICAL Consortium, Easton, Douglas, Eeles, Rosalind A, Muir, Kenneth, Amin Al Olama, Ali [0000-0002-7178-3431], Pharoah, Paul [0000-0001-8494-732X], Easton, Douglas [0000-0003-2444-3247], and Apollo - University of Cambridge Repository

Subjects
Male, Case-Control Studies, Humans, Prostatic Neoplasms, Gene-Environment Interaction, Middle Aged, Neoplasm Grading, Polymorphism, Single Nucleotide, Risk Assessment, APCB BioResource, Body Height, PRACTICAL consortium, Aged
Abstract

BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions. RESULTS: The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results